Abstracts Archive - Page 347 of 2425 - ACR Meeting Abstracts

Abstract Number: 2303 • ACR Convergence 2023
Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Jaime Vondenberg¹, Chao Zhang¹ and Emily Littlejohn², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…
Abstract Number: 2314 • ACR Convergence 2023
Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus
Emma Materne¹, Baijun Zhou¹, Hyon K. Choi², Yuqing Zhang³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Adolescent-onset SLE is associated with more severe disease than adult-onset SLE, but young adults may also experience adverse outcomes. We sought to compare disease…
Abstract Number: 2226 • ACR Convergence 2023
How Do Spondyloarthritis Start? Identification of the First Signs or Symptoms According to Diagnosis and HLA-B27. Data from REGISPONSER and RESPONDIA Registries
María Ángeles Puche Larrubia¹, Lourdes Ladehesa Pineda², Pilar Font Ugalde³, Alejandro Escudero Contreras⁴, Janitzia Vázquez Mellado⁵, Eduardo Collantes Estévez⁶ and Clementina López Medina⁷, ¹Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain, ⁵University Hospital of Mexico, Mexico City, Mexico, ⁶Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ⁷Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain
Background/Purpose: The definition for early spondyloarthritis (SpA) implies the correct identification of the initial symptom of SpA. There is currently no consensus on whether only…
Abstract Number: 2313 • ACR Convergence 2023
Utilization of Palliative Care in Hospitalized Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Analysis
Saman Tanveer¹, Hema Pinnam², Fatima Tanveer³ and Daksh Ahluwalia¹, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²J.S.S. Medical College, Mysore, India, ³CMH Lahore Medical College, Lahore, Pakistan
Background/Purpose: We aimed to investigate trends in utilization of hospital palliative care services among hospitalized patients with systemic lupus erythematosus (SLE) and analyze its impact…
Abstract Number: 2318 • ACR Convergence 2023
The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study
Vrati Mehra¹, Daniela Dominguez², Nicholas Gold², Andrea Knight², Deborah Levy², Fangming Liao², Eleanor Pullenayegum², Amer Shammas², etienne Sochett², Reza vali², Declan Webber³, Earl Silverman⁴ and Linda Hiraki², ¹The Hospital for Sick Children & University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴Silverman, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus patients < 18 years (cSLE) are at risk for reduced bone mineral density (BMD) due to disease activity and chronic…
Abstract Number: 2319 • ACR Convergence 2023
Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry
Clara Moriano Morales¹, Jaime Calvo- Alén², Iñigo Rúa-Figueroa³, MARIA ELVIRA DIEZ ALVAREZ¹, Cristina Bermúdez⁴, JULIA MARTINEZ BARRIO⁵, Maria Galindo-Izquierdo⁶, Alejandro Olivé-Marqués⁷, Eva Tomero Muriel⁸, Antonio Fernandez-Nebro⁹, Mercedes Freire González¹⁰, Olaia Fernandez-Berrizbeitia¹¹, Ana Pérez Gómez¹², Esther Uriarte Isacelaya¹³, carlos Marras Fernández-Cid¹⁴, Carlos Montilla-Morales¹⁵, Gregorio Santos Soler¹⁶, Ricardo Blanco¹⁷, Manuel Rodríguez-Gómez¹⁸, PALOMA VELA¹⁹, Alina Boteanu²⁰, Javier Narvaez²¹, Victor Martinez-Taboada²², Blanca Hernández-Cruz²³, Jose Luis Andreu-Sánchez²⁴, José Ángel Hernández Beriain²⁵, Lorena Expósito²⁶, Raúl Menor-Almagro²⁷, Mónica Ibáñez-Barceló²⁸, Ivan Castellvi²⁹, Carles Galisteo³⁰, Enrique Raya³¹, Víctor Quevedo-Vila³², Tomás Vazquez-Rodriguez³³, jesús Ibáñez³⁴ and Jose-Maria Pego-Reigosa³⁵, ¹Rheumatology, Hospital Universitario de León, León, Spain, ²Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ³Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Bioaraba Research Unit, Vitoria, Spain, ⁵Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁶Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Private Practice, Barcelona, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁰Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹¹Spanish Health Care Service, Bilbao, Spain, ¹²Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ¹³Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁴Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, ¹⁵Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ¹⁶Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁸Rheumatology, Hospital Ourense, Ourense, Spain, ¹⁹Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁰Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ²¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ²³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ²⁴Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁶Rheumatology, Hospital de Canarias, Tenerife, Spain, ²⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²⁸Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ³⁰Hospital Universitario Parc Taulí, Sabadell, Spain, ³¹Rheumatology, Hospital San Cecilio, Granada, Spain, ³²Rheumatology, Hospital Monforte de Lemos, Lugo, Spain, ³³Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³⁴Rheumatology, Hospital Ribera Povisa, Vigo, Spain, ³⁵Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences. We need to…
Abstract Number: 2227 • ACR Convergence 2023
The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Marion Pons², Merete Hetland², Bente Glintborg³, Jette Heberg², Sara Nysom Christiansen², Simon Horskjær Rasmussen², Anne Gitte Loft⁴, Isabel Castrejon⁵, Lucia Otero-Valera⁶, Jakub Zavada⁷, Karel Pavelka⁸, Heikki Relas⁹, Laura Kuusalo¹⁰, Burkhard Moeller¹¹, Michael Nissen¹², Ziga Rotar¹³, Katja Perdan Pirkmajer¹⁴, Daniela Santos Oliveira¹⁵, Ana Rita Cruz-Machado¹⁶, Brigitte Michelsen¹⁷, Eirik Kristianslund¹⁸, Bjorn Gudbjornsson¹⁹, Gerdur Maria Grondal²⁰, Karin Laas²¹, Pasoon Hellamand²², Ismail Sari²³, Daniela Di Giuseppe²⁴, Mikkel Østergaard²⁵ and Lykke Ørnbjerg², ¹Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ³Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁴Aarhus University, Horsens, Denmark, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Spanish Society of Rheumatology, Madrid, Spain, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Division of Internal Medicine, Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ¹¹Inselspital - University Hospital Bern, Bern, Switzerland, ¹²Geneva University Hospitals, Geneva, Switzerland, ¹³University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Department of Rheumatology, University Medical Centre LJubljana, Ljubljana, Slovenia, ¹⁵Department of Medicine, Faculty of Medicine, University of Porto, Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ¹⁶Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHULN, Academic Medical Center and ERN-ReCONNET; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa; Reuma.pt Sociedade Portuuesa de Reumatologia, Lisbon, Portugal, ¹⁷Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ¹⁸Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ²⁰Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²¹Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ²²Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²³Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁴Karolinska Institutet, Stockholm, Sweden, ²⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Smoking has been associated with higher disease activity, poorer treatment response, and drug retention rate among psoriatic arthritis (PsA) patients treated with Tumor Necrosis…
Abstract Number: 2273 • ACR Convergence 2023
Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
Vasileios Kyttaris¹, Tyler O'Malley², Giorgio Casaburi², Sudha Kumar² and Andrew Concoff³, ¹BIDMC, Boston, MA, ²Exagen, Vista, CA, ³Exagen, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease with diverse clinical manifestations and variable treatment response. Conventional biomarkers of SLE activityprovide modest correlation…
Abstract Number: 2304 • ACR Convergence 2023
Disparity in Healthcare in Systemic Lupus Erythematosus: A Single-Center Study
Joshua Reed, Anam Nazir, Khalid Alghamdi and Catherine Ivory, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is variable in clinical presentation and has fluctuating disease severity. Health outcomes in SLE have been linked to both genetic…
Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Arthur Mageau¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
Abstract Number: 2233 • ACR Convergence 2023
Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials
Thomas Macleod¹, Xenofon Baraliakos², Emmanouil Rampakakis³, Warner Chen⁴, Antonius Pieter J Van Den Heuvel⁴, Loqmane Seridi⁴, May Shawi⁵, Frederic Lavie⁶, Joseph F. Merola⁷, Proton Rahman⁸ and Dennis McGonagle⁹, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁴Translational Sciences, Janssen Research & Development, LLC, Spring House, PA, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁹Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Neutrophils have potential pathogenic roles in chronic inflammatory diseases (e.g., neutrophilic cutaneous microabscesses in psoriasis, and neutrophils in the synovial fluid/tissue in PsA and…
Abstract Number: 2237 • ACR Convergence 2023
Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice
Eva Galindez-Agirregoikoa¹, Diana Prieto-Peña², Maria Luz Garcia Vivar¹, Lucia Vega-Alvarez¹, Cristina Vergara³, Irati Urionaguena⁴, Consuelo Ramos-Giráldez⁵, Raquel Almodovar⁶, Beatriz Joven Ibáñez⁷, Rosario Garcia-Vicuna⁸, Vega Jovani⁹, Teresa González¹⁰, Àngels Martínez-Ferrer¹¹, Ana Urruticoechea Arana¹², Bryan Josue Flores Robles¹³, Cristina Campos Fernández¹⁴, Lilian Maria Lopez Nunez¹⁵, Joaquin Maria Belzunegui Otano¹⁶, Marina Pavia Pascual¹⁷, Esteban Rubio¹⁸, Angel Ramos-Calvo¹⁹, Noemi Busquets²⁰, Ana Pérez Gómez²¹, Francisco Miguel Ortiz Sanjuan²², Rafael Benito Melero-Gonzalez²³, Cristina Macía²⁴, María Ángeles Puche Larrubia²⁵, Jose Antonio Pinto Tasende²⁶, Cristina Fernandez²⁷, Maria Paz Martinez-Vidal²⁸, Jaime Calvo- Alén²⁹, Emma Beltran-Catalan³⁰, Mireia Moreno³¹, Silvia Pérez-Barrio³², iñigo Gorostiza Hormaeche¹ and Ricardo Blanco³³, ¹Basurto University Hospital, Bilbao, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴GALDAKAO-USANSOLO UNIVERSITY HOSPITAL, GERNIKA-LUMO, Spain, ⁵Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ⁶Alcorcón Foundation University Hospital, Madrid, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹¹Hospital Universitario Dr Peset Valéncia, Valéncia, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Hospital Universitario San Pedro, Logroño, Spain, ¹⁴Hospital General Universitario Valencia, Valencia, Spain, ¹⁵Son llatzer, Palmanyola, Spain, ¹⁶University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁷Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁸Servicio Andaluz Salud, Sevilla, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ²¹Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²²Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²³CHU Vigo, O Carballino, Spain, ²⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁵Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ²⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁷Hospital Universitario San Juan de Alicante, Alicante, Spain, ²⁸Hospital Universitario San Juan Alicante, Alicante, Spain, ²⁹Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ³⁰HOSPITAL DEL MAR, Barcelona, Spain, ³¹Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³²Hospital Universitario de Basurto, Bilbao, Spain, ³³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The EMA authorized Upadacitinib (UPA) in PsA in January 2021. UPA has shown efficacy in PsA refractory to anti-TNF in a clinical trial (RCT).…
Abstract Number: 2298 • ACR Convergence 2023
SLE Patients Are at High Risk for Tuberculosis Infection: Data from a Lupus Center of an Endemic Country
Victor Leda¹, Andreia Sousa¹, Fernanda Lopes¹, Emily Neves¹, Sandra Pasoto², Danieli Andrade², Michelle Ugolini¹, Eloisa Bonfa², Eduardo Borba¹, Adriana Tonacio¹ and Luciana Seguro¹, ¹Hospital das Clinicas HCFMUSP, University of São Paulo, São Paulo, Brazil, ²University of São Paulo, São Paulo, Brazil
Background/Purpose: SLE patients are at high risk for tuberculosis (TB) infection especially in endemic countries. Despite the importance of this infection condition, there are still…
Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Dr Hiba Khogali¹, Ghada Al‐Bluwi², Virgie Guy² and Ali Al Dhanhani³, ¹Tawam Hospital, Al Ain, United Arab Emirates, ²College of Medicine, UAE University, Al Ain, United Arab Emirates, ³UAE University, Al Ain, United Arab Emirates
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
Abstract Number: 2326 • ACR Convergence 2023
Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g
Emily Littlejohn¹, Salem Almaani², Vanessa Birardi³, Ernie Yap⁴ and Christopher Collins⁵, ¹Cleveland Clinic, Cleveland, OH, ²Ohio State University Medical Center, Columbus, OH, ³Aurinia Pharmaceuticals Inc, Edmonton, AB, Canada, ⁴Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ⁵Formerly Aurinia Pharmaceuticals Inc., Copenhagen, Denmark
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis and is a mediator of progressive kidney damage. Early reductions in urine protein creatinine ratio…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].